Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) insider Heidy King-Jones sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $90.00, for a total value of $36,000.00. Following the sale, the insider directly owned 2,845 shares of the company’s stock, valued at $256,050. This represents a 12.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heidy King-Jones also recently made the following trade(s):

• On Tuesday, September 1st, Heidy King-Jones sold 27,999 shares of Spyre Therapeutics stock. The shares were sold at an average price of $87.31, for a total transaction of $2,444,592.69.

Spyre Therapeutics Price Performance

Shares of NASDAQ:SYRE opened at $88.98 on Friday. The stock has a market cap of $7.82 billion, a price-to-earnings ratio of -45.63 and a beta of 2.99. The company has a 50 day moving average of $98.05 and a 200-day moving average of $74.63. Spyre Therapeutics, Inc. has a one year low of $14.51 and a one year high of $110.18.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.40. Equities research analysts anticipate that Spyre Therapeutics, Inc. will post -2.62 earnings per share for the current year.

Hedge Funds Weigh In On Spyre Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SYRE. Allianz Asset Management GmbH acquired a new stake in Spyre Therapeutics during the 2nd quarter worth approximately $1,252,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Spyre Therapeutics in the second quarter valued at approximately $999,000. California State Teachers Retirement System boosted its holdings in shares of Spyre Therapeutics by 9,594.0% in the second quarter. California State Teachers Retirement System now owns 5,742,912 shares of the company’s stock valued at $509,856,000 after buying an additional 5,683,670 shares during the period. Nykredit A S bought a new stake in shares of Spyre Therapeutics during the second quarter worth $173,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Spyre Therapeutics during the second quarter worth $21,768,000. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Spyre Therapeutics News Summary

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Management will participate in the Citi BioPharma Back to School Conference on September 9, the Wells Fargo Healthcare Conference on September 10, and the Stifel Immunology and Inflammation Forum on September 23. These events could provide updates on Spyre’s clinical programs, development strategy, and potential catalysts. Spyre Therapeutics to Participate in Upcoming September Investor Conferences
• Positive Sentiment: Spyre’s independent compensation committee approved stock options covering 2,106 shares and 745 restricted stock units for a new non-executive employee. The awards were intended to secure the employee’s acceptance and may support the company’s ability to recruit talent, although the equity issuance has a modest dilution effect. Spyre Therapeutics Announces Grants of Inducement Awards
• Neutral Sentiment: Spyre’s latest quarterly loss of $0.36 per share was better than the expected $0.76 loss. However, the company remains unprofitable, with analysts forecasting a full-year loss of approximately $2.62 per share. The earnings beat alone has not provided a lasting catalyst.
• Negative Sentiment: Several insiders reported sales totaling roughly 69,000 shares. CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold 25,732 shares, and Heidy King-Jones sold 28,399 shares. The transactions were made under pre-arranged Rule 10b5-1 plans; Burrows said his sales covered tax withholding obligations. Even so, the volume of selling—particularly King-Jones’s substantial reduction in ownership—could weigh on investor sentiment. Spyre Therapeutics Insider Trading
• Negative Sentiment: A Zacks report noted that SYRE had declined 16.6% since its latest earnings release, suggesting investors remain focused on the need for clinical progress and additional company-specific catalysts. Spyre Therapeutics Down 16.6% Since Last Earnings Report

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on SYRE shares. Wells Fargo & Company boosted their target price on Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Guggenheim boosted their price objective on shares of Spyre Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Wolfe Research downgraded shares of Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Tuesday. Finally, Wedbush reduced their price target on shares of Spyre Therapeutics from $130.00 to $123.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $109.69.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.